{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:18:42Z","timestamp":1790039922557,"version":"4.0.1"},"reference-count":18,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2016,2,4]]},"published-print":{"date-parts":[[2016,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this study was to evaluate trends in prescribing of the second-generation antipsychotic medication quetiapine to adults in the province of Alberta from 2008 to 2013 through examination of dispensed prescriptions, and diagnoses associated with users of quetiapine in 2013.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed administrative data from Alberta Health; the Alberta Pharmaceutical Information Network (PIN) Dispenses health data set, the Practitioner Payments (Fee-For-Service claims) health data set and the Population Registry health data set. These data sets allowed us to identify discrete quetiapine recipients for each calendar year from 2008 to 2013. To evaluate diagnoses associated with users of quetiapine, we evaluated diagnostic codes used by physicians in billings claims in 2013.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Quetiapine use increased over the 6-year time period studied. In 2008, there were 16\u2005087 unique quetiapine recipients in Alberta (7.2 per 1000). By 2013, there were 35\u2005314 unique quetiapine recipients (13.3 per 1000). Use by women was higher than men at all time points. Depression was most common diagnosis associated with quetiapine recipients, which was present in 56% of users of quetiapine. Other common diagnoses associated with quetiapine use included neurotic disorders, bipolar disorder and sleep disturbances.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The current study of quetiapine use in the province of Alberta provides confirmatory data of the increasing use of quetiapine for the treatment of depression and anxiety disorders. Safe and rational prescribing practices must be encouraged in light of the modest advantages of quetiapine over no treatment as an adjunctive treatment of major depression, and the known harms of this medication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2015-010861","type":"journal-article","created":{"date-parts":[[2016,3,21]],"date-time":"2016-03-21T23:37:00Z","timestamp":1458603420000},"page":"e010861","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":33,"title":["Quetiapine use in adults in the community: a population-based study in Alberta, Canada"],"prefix":"10.1136","volume":"6","author":[{"given":"Diane","family":"Duncan","sequence":"first","affiliation":[{"name":"Physician Learning Program, Continuing Medical Education and Professional Development, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Cooke","sequence":"additional","affiliation":[{"name":"Physician Learning Program, Continuing Medical Education and Professional Development, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"},{"name":"Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Symonds","sequence":"additional","affiliation":[{"name":"Physician Learning Program, Continuing Medical Education and Professional Development, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gardner","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Pringsheim","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada"},{"name":"Mathison Centre for Mental Health Research and Education, University of Calgary, Calgary, Alberta, Canada"},{"name":"Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,3,21]]},"reference":[{"key":"2025121600143041000_6.3.e010861.1","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20140009"},{"key":"2025121600143041000_6.3.e010861.2","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2010.0073"},{"key":"2025121600143041000_6.3.e010861.3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/070674371205700109","article-title":"Ten years of antipsychotic prescribing to children: a Canadian population-based study","volume":"57","author":"Alessi-Severini","year":"2012","journal-title":"Can J Psychiatry"},{"key":"2025121600143041000_6.3.e010861.4","doi-asserted-by":"publisher","DOI":"10.2165\/11592020-000000000-00000"},{"key":"2025121600143041000_6.3.e010861.5","doi-asserted-by":"crossref","unstructured":"Gardner DM , Teehan MD . Antipsychotics and their side effects. Cambridge: Cambridge University Press, 2010.","DOI":"10.1017\/CBO9780511919237"},{"key":"2025121600143041000_6.3.e010861.6","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/pch\/16.9.581","article-title":"Evidence based recommendations for monitoring safety of second generation antipsychotics in children and youth","volume":"16","author":"Pringsheim","year":"2011","journal-title":"Pediatr Child Health"},{"key":"2025121600143041000_6.3.e010861.7","doi-asserted-by":"publisher","DOI":"10.1177\/070674371506000106"},{"key":"2025121600143041000_6.3.e010861.8","unstructured":"Overview of Administrative Health Datasets2015 2015.01.13. http:\/\/www.health.alberta.ca\/documents\/Research-Health-Datasets.pdf"},{"key":"2025121600143041000_6.3.e010861.9","unstructured":"Health Canada Drug Product Database Data Extract Files2015 2015.01.13. http:\/\/hc-sc.gc.ca\/dhp-mps\/prodpharma\/databasdon\/dpd_bdpp_data_extract-eng.php"},{"key":"2025121600143041000_6.3.e010861.10","unstructured":"Alberta Health Claims Assessment Alberta Health Diagnostic Codes2015 2015.01.13. http:\/\/www.health.alberta.ca\/documents\/Diagnostic-Code-ICD-9.pdf"},{"key":"2025121600143041000_6.3.e010861.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h569"},{"key":"2025121600143041000_6.3.e010861.12","doi-asserted-by":"crossref","unstructured":"Depping AM , Komossa K , Kissling W , et al . Second generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev 2010;(12):CD008120.","DOI":"10.1002\/14651858.CD008120.pub2"},{"key":"2025121600143041000_6.3.e010861.13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.708"},{"key":"2025121600143041000_6.3.e010861.14","unstructured":"Allied Health Practitioner's Resource Guide2015 2015.01.13. http:\/\/www.health.alberta.ca\/documents\/Allied-Practitioners-Guide-2014.pdf"},{"key":"2025121600143041000_6.3.e010861.15","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-7-682"},{"key":"2025121600143041000_6.3.e010861.16","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.111.104257"},{"key":"2025121600143041000_6.3.e010861.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006135"},{"key":"2025121600143041000_6.3.e010861.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2013.09.006"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2015-010861","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:14:45Z","timestamp":1765872885000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2015-010861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,3,21]]},"published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1136\/bmjopen-2015-010861"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2015-010861","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}